Effectiveness of COVID-19 vaccination in healthcare workers in Shiga Prefecture, Japan

This study, which included serological and cellular immunity tests, evaluated whether coronavirus disease 2019 (COVID-19) vaccination adequately protected healthcare workers (HCWs) from COVID-19. Serological investigations were conducted among 1600 HCWs (mean ± standard deviation, 7.4 ± 1.4 months a...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 12; no. 1; pp. 17621 - 9
Main Authors Chano, Tokuhiro, Yamashita, Tomoko, Fujimura, Hirokazu, Kita, Hiroko, Ikemoto, Toshiyuki, Kume, Shinji, Morita, Shin-ya, Suzuki, Tomoyuki, Kakuno, Fumihiko
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 21.10.2022
Nature Publishing Group
Nature Portfolio
Subjects
Online AccessGet full text
ISSN2045-2322
2045-2322
DOI10.1038/s41598-022-22682-3

Cover

Abstract This study, which included serological and cellular immunity tests, evaluated whether coronavirus disease 2019 (COVID-19) vaccination adequately protected healthcare workers (HCWs) from COVID-19. Serological investigations were conducted among 1600 HCWs (mean ± standard deviation, 7.4 ± 1.4 months after the last COVID-19 vaccination). Anti-SARS-CoV-2 antibodies N-Ig, Spike-Ig (Roche), N-IgG, Spike-IgM, and -IgG (Abbott), were evaluated using a questionnaire of health condition. 161 HCWs were analyzed for cellular immunity using T-SPOT ® SARS-CoV-2 kit before, and 52 HCWs were followed up until 138.3 ± 15.7 days after their third vaccination. Spike-IgG value was 954.4 ± 2282.6 AU/mL. Forty-nine of the 1600 HCWs (3.06%) had pre-existing SARS-CoV-2 infection. None of the infectious seropositive HCWs required hospitalization. T-SPOT value was 85.0 ± 84.2 SFU/10 6 cells before the third vaccination, which increased to 219.4 ± 230.4 SFU/10 6 cells immediately after, but attenuated later (to 111.1 ± 133.6 SFU/10 6 cells). Poor counts (< 40 SFU/10 6 cells) were present in 34.8% and 38.5% of HCWs before and after the third vaccination, respectively. Our findings provide insights into humoral and cellular immune responses to repeated COVID-19 vaccinations. COVID-19 vaccination was effective in protecting HCWs from serious illness during the original Wuhan-1, Alpha, Delta and also ongoing Omicron-predominance periods. However, repeated vaccinations using current vaccine versions may not induce sufficient cellular immunity in all HCWs.
AbstractList Abstract This study, which included serological and cellular immunity tests, evaluated whether coronavirus disease 2019 (COVID-19) vaccination adequately protected healthcare workers (HCWs) from COVID-19. Serological investigations were conducted among 1600 HCWs (mean ± standard deviation, 7.4 ± 1.4 months after the last COVID-19 vaccination). Anti-SARS-CoV-2 antibodies N-Ig, Spike-Ig (Roche), N-IgG, Spike-IgM, and -IgG (Abbott), were evaluated using a questionnaire of health condition. 161 HCWs were analyzed for cellular immunity using T-SPOT® SARS-CoV-2 kit before, and 52 HCWs were followed up until 138.3 ± 15.7 days after their third vaccination. Spike-IgG value was 954.4 ± 2282.6 AU/mL. Forty-nine of the 1600 HCWs (3.06%) had pre-existing SARS-CoV-2 infection. None of the infectious seropositive HCWs required hospitalization. T-SPOT value was 85.0 ± 84.2 SFU/106 cells before the third vaccination, which increased to 219.4 ± 230.4 SFU/106 cells immediately after, but attenuated later (to 111.1 ± 133.6 SFU/106 cells). Poor counts (< 40 SFU/106 cells) were present in 34.8% and 38.5% of HCWs before and after the third vaccination, respectively. Our findings provide insights into humoral and cellular immune responses to repeated COVID-19 vaccinations. COVID-19 vaccination was effective in protecting HCWs from serious illness during the original Wuhan-1, Alpha, Delta and also ongoing Omicron-predominance periods. However, repeated vaccinations using current vaccine versions may not induce sufficient cellular immunity in all HCWs.
This study, which included serological and cellular immunity tests, evaluated whether coronavirus disease 2019 (COVID-19) vaccination adequately protected healthcare workers (HCWs) from COVID-19. Serological investigations were conducted among 1600 HCWs (mean ± standard deviation, 7.4 ± 1.4 months after the last COVID-19 vaccination). Anti-SARS-CoV-2 antibodies N-Ig, Spike-Ig (Roche), N-IgG, Spike-IgM, and -IgG (Abbott), were evaluated using a questionnaire of health condition. 161 HCWs were analyzed for cellular immunity using T-SPOT ® SARS-CoV-2 kit before, and 52 HCWs were followed up until 138.3 ± 15.7 days after their third vaccination. Spike-IgG value was 954.4 ± 2282.6 AU/mL. Forty-nine of the 1600 HCWs (3.06%) had pre-existing SARS-CoV-2 infection. None of the infectious seropositive HCWs required hospitalization. T-SPOT value was 85.0 ± 84.2 SFU/10 6 cells before the third vaccination, which increased to 219.4 ± 230.4 SFU/10 6 cells immediately after, but attenuated later (to 111.1 ± 133.6 SFU/10 6 cells). Poor counts (< 40 SFU/10 6 cells) were present in 34.8% and 38.5% of HCWs before and after the third vaccination, respectively. Our findings provide insights into humoral and cellular immune responses to repeated COVID-19 vaccinations. COVID-19 vaccination was effective in protecting HCWs from serious illness during the original Wuhan-1, Alpha, Delta and also ongoing Omicron-predominance periods. However, repeated vaccinations using current vaccine versions may not induce sufficient cellular immunity in all HCWs.
This study, which included serological and cellular immunity tests, evaluated whether coronavirus disease 2019 (COVID-19) vaccination adequately protected healthcare workers (HCWs) from COVID-19. Serological investigations were conducted among 1600 HCWs (mean ± standard deviation, 7.4 ± 1.4 months after the last COVID-19 vaccination). Anti-SARS-CoV-2 antibodies N-Ig, Spike-Ig (Roche), N-IgG, Spike-IgM, and -IgG (Abbott), were evaluated using a questionnaire of health condition. 161 HCWs were analyzed for cellular immunity using T-SPOT SARS-CoV-2 kit before, and 52 HCWs were followed up until 138.3 ± 15.7 days after their third vaccination. Spike-IgG value was 954.4 ± 2282.6 AU/mL. Forty-nine of the 1600 HCWs (3.06%) had pre-existing SARS-CoV-2 infection. None of the infectious seropositive HCWs required hospitalization. T-SPOT value was 85.0 ± 84.2 SFU/10 cells before the third vaccination, which increased to 219.4 ± 230.4 SFU/10 cells immediately after, but attenuated later (to 111.1 ± 133.6 SFU/10 cells). Poor counts (< 40 SFU/10 cells) were present in 34.8% and 38.5% of HCWs before and after the third vaccination, respectively. Our findings provide insights into humoral and cellular immune responses to repeated COVID-19 vaccinations. COVID-19 vaccination was effective in protecting HCWs from serious illness during the original Wuhan-1, Alpha, Delta and also ongoing Omicron-predominance periods. However, repeated vaccinations using current vaccine versions may not induce sufficient cellular immunity in all HCWs.
This study, which included serological and cellular immunity tests, evaluated whether coronavirus disease 2019 (COVID-19) vaccination adequately protected healthcare workers (HCWs) from COVID-19. Serological investigations were conducted among 1600 HCWs (mean ± standard deviation, 7.4 ± 1.4 months after the last COVID-19 vaccination). Anti-SARS-CoV-2 antibodies N-Ig, Spike-Ig (Roche), N-IgG, Spike-IgM, and -IgG (Abbott), were evaluated using a questionnaire of health condition. 161 HCWs were analyzed for cellular immunity using T-SPOT® SARS-CoV-2 kit before, and 52 HCWs were followed up until 138.3 ± 15.7 days after their third vaccination. Spike-IgG value was 954.4 ± 2282.6 AU/mL. Forty-nine of the 1600 HCWs (3.06%) had pre-existing SARS-CoV-2 infection. None of the infectious seropositive HCWs required hospitalization. T-SPOT value was 85.0 ± 84.2 SFU/106 cells before the third vaccination, which increased to 219.4 ± 230.4 SFU/106 cells immediately after, but attenuated later (to 111.1 ± 133.6 SFU/106 cells). Poor counts (< 40 SFU/106 cells) were present in 34.8% and 38.5% of HCWs before and after the third vaccination, respectively. Our findings provide insights into humoral and cellular immune responses to repeated COVID-19 vaccinations. COVID-19 vaccination was effective in protecting HCWs from serious illness during the original Wuhan-1, Alpha, Delta and also ongoing Omicron-predominance periods. However, repeated vaccinations using current vaccine versions may not induce sufficient cellular immunity in all HCWs.This study, which included serological and cellular immunity tests, evaluated whether coronavirus disease 2019 (COVID-19) vaccination adequately protected healthcare workers (HCWs) from COVID-19. Serological investigations were conducted among 1600 HCWs (mean ± standard deviation, 7.4 ± 1.4 months after the last COVID-19 vaccination). Anti-SARS-CoV-2 antibodies N-Ig, Spike-Ig (Roche), N-IgG, Spike-IgM, and -IgG (Abbott), were evaluated using a questionnaire of health condition. 161 HCWs were analyzed for cellular immunity using T-SPOT® SARS-CoV-2 kit before, and 52 HCWs were followed up until 138.3 ± 15.7 days after their third vaccination. Spike-IgG value was 954.4 ± 2282.6 AU/mL. Forty-nine of the 1600 HCWs (3.06%) had pre-existing SARS-CoV-2 infection. None of the infectious seropositive HCWs required hospitalization. T-SPOT value was 85.0 ± 84.2 SFU/106 cells before the third vaccination, which increased to 219.4 ± 230.4 SFU/106 cells immediately after, but attenuated later (to 111.1 ± 133.6 SFU/106 cells). Poor counts (< 40 SFU/106 cells) were present in 34.8% and 38.5% of HCWs before and after the third vaccination, respectively. Our findings provide insights into humoral and cellular immune responses to repeated COVID-19 vaccinations. COVID-19 vaccination was effective in protecting HCWs from serious illness during the original Wuhan-1, Alpha, Delta and also ongoing Omicron-predominance periods. However, repeated vaccinations using current vaccine versions may not induce sufficient cellular immunity in all HCWs.
This study, which included serological and cellular immunity tests, evaluated whether coronavirus disease 2019 (COVID-19) vaccination adequately protected healthcare workers (HCWs) from COVID-19. Serological investigations were conducted among 1600 HCWs (mean ± standard deviation, 7.4 ± 1.4 months after the last COVID-19 vaccination). Anti-SARS-CoV-2 antibodies N-Ig, Spike-Ig (Roche), N-IgG, Spike-IgM, and -IgG (Abbott), were evaluated using a questionnaire of health condition. 161 HCWs were analyzed for cellular immunity using T-SPOT® SARS-CoV-2 kit before, and 52 HCWs were followed up until 138.3 ± 15.7 days after their third vaccination. Spike-IgG value was 954.4 ± 2282.6 AU/mL. Forty-nine of the 1600 HCWs (3.06%) had pre-existing SARS-CoV-2 infection. None of the infectious seropositive HCWs required hospitalization. T-SPOT value was 85.0 ± 84.2 SFU/106 cells before the third vaccination, which increased to 219.4 ± 230.4 SFU/106 cells immediately after, but attenuated later (to 111.1 ± 133.6 SFU/106 cells). Poor counts (< 40 SFU/106 cells) were present in 34.8% and 38.5% of HCWs before and after the third vaccination, respectively. Our findings provide insights into humoral and cellular immune responses to repeated COVID-19 vaccinations. COVID-19 vaccination was effective in protecting HCWs from serious illness during the original Wuhan-1, Alpha, Delta and also ongoing Omicron-predominance periods. However, repeated vaccinations using current vaccine versions may not induce sufficient cellular immunity in all HCWs.
This study, which included serological and cellular immunity tests, evaluated whether coronavirus disease 2019 (COVID-19) vaccination adequately protected healthcare workers (HCWs) from COVID-19. Serological investigations were conducted among 1600 HCWs (mean ± standard deviation, 7.4 ± 1.4 months after the last COVID-19 vaccination). Anti-SARS-CoV-2 antibodies N-Ig, Spike-Ig (Roche), N-IgG, Spike-IgM, and -IgG (Abbott), were evaluated using a questionnaire of health condition. 161 HCWs were analyzed for cellular immunity using T-SPOT® SARS-CoV-2 kit before, and 52 HCWs were followed up until 138.3 ± 15.7 days after their third vaccination. Spike-IgG value was 954.4 ± 2282.6 AU/mL. Forty-nine of the 1600 HCWs (3.06%) had pre-existing SARS-CoV-2 infection. None of the infectious seropositive HCWs required hospitalization. T-SPOT value was 85.0 ± 84.2 SFU/106 cells before the third vaccination, which increased to 219.4 ± 230.4 SFU/106 cells immediately after, but attenuated later (to 111.1 ± 133.6 SFU/106 cells). Poor counts (< 40 SFU/106 cells) were present in 34.8% and 38.5% of HCWs before and after the third vaccination, respectively. Our findings provide insights into humoral and cellular immune responses to repeated COVID-19 vaccinations. COVID-19 vaccination was effective in protecting HCWs from serious illness during the original Wuhan-1, Alpha, Delta and also ongoing Omicron-predominance periods. However, repeated vaccinations using current vaccine versions may not induce sufficient cellular immunity in all HCWs.
ArticleNumber 17621
Author Kume, Shinji
Kakuno, Fumihiko
Chano, Tokuhiro
Kita, Hiroko
Ikemoto, Toshiyuki
Morita, Shin-ya
Suzuki, Tomoyuki
Fujimura, Hirokazu
Yamashita, Tomoko
Author_xml – sequence: 1
  givenname: Tokuhiro
  surname: Chano
  fullname: Chano, Tokuhiro
  email: chano@belle.shiga-med.ac.jp
  organization: Department of Clinical Laboratory Medicine, Shiga University of Medical Science Hospital
– sequence: 2
  givenname: Tomoko
  surname: Yamashita
  fullname: Yamashita, Tomoko
  organization: Department of Clinical Laboratory Medicine, Shiga University of Medical Science Hospital
– sequence: 3
  givenname: Hirokazu
  surname: Fujimura
  fullname: Fujimura, Hirokazu
  organization: Department of Clinical Laboratory Medicine, Shiga University of Medical Science Hospital
– sequence: 4
  givenname: Hiroko
  surname: Kita
  fullname: Kita, Hiroko
  organization: Department of Clinical Laboratory Medicine, Shiga University of Medical Science Hospital
– sequence: 5
  givenname: Toshiyuki
  surname: Ikemoto
  fullname: Ikemoto, Toshiyuki
  organization: Department of Clinical Laboratory Medicine, Shiga University of Medical Science Hospital
– sequence: 6
  givenname: Shinji
  surname: Kume
  fullname: Kume, Shinji
  organization: Department of Nephrology, Shiga University of Medical Science Hospital
– sequence: 7
  givenname: Shin-ya
  surname: Morita
  fullname: Morita, Shin-ya
  organization: Department of Pharmacy, Shiga University of Medical Science Hospital
– sequence: 8
  givenname: Tomoyuki
  surname: Suzuki
  fullname: Suzuki, Tomoyuki
  organization: Shiga Prefecture Administration
– sequence: 9
  givenname: Fumihiko
  surname: Kakuno
  fullname: Kakuno, Fumihiko
  organization: Shiga Prefecture Administration
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36271136$$D View this record in MEDLINE/PubMed
BookMark eNqNkUtv1DAUhSNURB_0D7BAkdiwIOB3nA0SGgoMqlQkoFvrxrFnPGTsqZ1M1X9fz4PSdlFxN7auz_10fO5xceCDN0XxCqP3GFH5ITHMG1khQipChCQVfVYcEcR4RSghB_fuh8VpSguUi5OG4eZFcUgFqTGm4qi4PLPW6MGtjTcplcGWk4vL6ecKN-UatHYeBhd86Xw5N9APcw3RlNch_jExbbo_524G5Y9oNpQxmnfld1iBf1k8t9Anc7o_T4rfX85-Tb5V5xdfp5NP55UWHA2VRTUHq42owdak6ZgFadoOd1wCE7o1lmItMePUslZabFEDAqPaYI46yVp6Ukx33C7AQq2iW0K8UQGc2jZCnCmIg9O9UYgzTIzU0lLBaAeSSoYoaTvISNxBZtEda_QruLmGvr8DYqQ2oatd6CqHrrahK5qnPu6mVmO7NJ02fojQP7Dy8MW7uZqFtWq4FA0XGfB2D4jhajRpUEuXtOl78CaMSZGa1II2ubL0zSPpIozR54C3KowlpRvV6_uO7qz8XXoWyJ1Ax5BSXp3SbtjuORt0_dO_JY9G_yuifbApi_3MxH-2n5i6BR1H4Bw
CitedBy_id crossref_primary_10_1177_25151355231181744
crossref_primary_10_1186_s13256_024_04889_2
crossref_primary_10_1186_s12879_024_09001_z
Cites_doi 10.1056/NEJMoa2114228
10.1038/s41586-022-04465-y
10.1016/s2213-2600(22)00101-1
10.1016/j.diagmicrobio.2021.115370
10.1056/NEJMoa2114583
10.1038/s41586-022-04778-y
10.1016/j.lanepe.2021.100208
10.1016/s0140-6736(21)00501-8
10.1016/s0140-6736(21)00502-x
10.1126/sciimmunol.abo2202
10.3390/ijerph18073786
10.1038/bmt.2012.244
10.1016/j.cell.2022.04.009
10.1093/infdis/jiab584
10.1101/2020.11.02.20222778
10.1016/s0140-6736(21)01642-1
10.1038/s41591-022-01700-x
10.1371/journal.pone.0270334
10.1038/s41590-021-01122-w
10.1038/s41586-022-04460-3
10.1016/s1473-3099(22)00271-7
10.3390/v14040802
10.3390/jcm9123989
10.1038/s42003-021-02885-6
10.1093/cid/ciab1041
10.1136/bmj.m3944
10.1101/2020.04.29.20085449
10.1016/j.diagmicrobio.2021.115403
10.1016/j.diagmicrobio.2021.115313
ContentType Journal Article
Copyright The Author(s) 2022
2022. The Author(s).
The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2022
– notice: 2022. The Author(s).
– notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88A
88E
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
Q9U
7X8
5PM
ADTOC
UNPAY
DOA
DOI 10.1038/s41598-022-22682-3
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Journals
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central
ProQuest Central Essentials - QC
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Science Database
Biological Science Database
Proquest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
CrossRef
MEDLINE

MEDLINE - Academic
Publicly Available Content Database

Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
– sequence: 6
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2045-2322
EndPage 9
ExternalDocumentID oai_doaj_org_article_05412e8c8f3643da8384032bdaa611da
10.1038/s41598-022-22682-3
PMC9586956
36271136
10_1038_s41598_022_22682_3
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Japan
GeographicLocations_xml – name: Japan
GrantInformation_xml – fundername: Shiga Prefecture Governor
  grantid: PT330033
– fundername: ;
  grantid: PT330033
GroupedDBID 0R~
3V.
4.4
53G
5VS
7X7
88A
88E
88I
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AAKDD
ABDBF
ABUWG
ACGFS
ACSMW
ACUHS
ADBBV
ADRAZ
AENEX
AEUYN
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
EBD
EBLON
EBS
ESX
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
KQ8
LK8
M0L
M1P
M2P
M48
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNT
RNTTT
RPM
SNYQT
UKHRP
AASML
AAYXX
AFPKN
CITATION
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
PUEGO
CGR
CUY
CVF
ECM
EIF
NPM
7XB
8FK
K9.
PKEHL
PQEST
PQUKI
Q9U
7X8
5PM
ADTOC
EJD
IPNFZ
RIG
UNPAY
ID FETCH-LOGICAL-c650t-f075afce67af729d4fa8ebd1d58a46cbef31c81453f4b8f1f09a6107e150d84b3
IEDL.DBID M48
ISSN 2045-2322
IngestDate Fri Oct 03 12:43:29 EDT 2025
Sun Oct 26 03:41:46 EDT 2025
Tue Sep 30 17:18:17 EDT 2025
Thu Oct 02 11:11:22 EDT 2025
Tue Oct 07 07:56:11 EDT 2025
Thu Jan 02 22:53:41 EST 2025
Wed Oct 01 01:37:48 EDT 2025
Thu Apr 24 23:06:53 EDT 2025
Fri Feb 21 02:39:21 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2022. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
cc-by
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c650t-f075afce67af729d4fa8ebd1d58a46cbef31c81453f4b8f1f09a6107e150d84b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1038/s41598-022-22682-3
PMID 36271136
PQID 2727118339
PQPubID 2041939
PageCount 9
ParticipantIDs doaj_primary_oai_doaj_org_article_05412e8c8f3643da8384032bdaa611da
unpaywall_primary_10_1038_s41598_022_22682_3
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9586956
proquest_miscellaneous_2727639999
proquest_journals_2727118339
pubmed_primary_36271136
crossref_citationtrail_10_1038_s41598_022_22682_3
crossref_primary_10_1038_s41598_022_22682_3
springer_journals_10_1038_s41598_022_22682_3
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-10-21
PublicationDateYYYYMMDD 2022-10-21
PublicationDate_xml – month: 10
  year: 2022
  text: 2022-10-21
  day: 21
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Scientific reports
PublicationTitleAbbrev Sci Rep
PublicationTitleAlternate Sci Rep
PublicationYear 2022
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Muecksch (CR24) 2022; 607
Kanda (CR15) 2013; 48
Liu (CR28) 2022; 603
CR17
Levin (CR21) 2021; 385
GeurtsvanKessel (CR29) 2022; 7
Moss (CR5) 2022; 23
Stouten (CR16) 2022; 14
Lu (CR26) 2021
Shrotri (CR20) 2021; 398
Prendecki (CR13) 2021; 397
Yoshihara (CR1) 2021; 18
Gilboa (CR25) 2021
Schaffner (CR10) 2020; 9
Keeton (CR27) 2022; 603
Tartof (CR7) 2022
Karlsson, Fraenkel (CR18) 2020; 371
CR4
Tanis (CR8) 2021; 100
Takita (CR2) 2020
Goldberg (CR22) 2021; 385
Gao (CR31) 2022; 28
Chano (CR3) 2022; 17
Wyllie (CR14) 2020
Goel (CR30) 2022; 185
Manisty (CR11) 2021; 397
Kubota (CR12) 2021; 100
Schallier (CR9) 2021; 100
Naaber (CR19) 2021
Shimizu (CR23) 2021; 4
Munro (CR6) 2022
SY Tartof (22682_CR7) 2022
K Kubota (22682_CR12) 2021; 100
U Karlsson (22682_CR18) 2020; 371
M Prendecki (22682_CR13) 2021; 397
M Shrotri (22682_CR20) 2021; 398
P Naaber (22682_CR19) 2021
RR Goel (22682_CR30) 2022; 185
Y Gao (22682_CR31) 2022; 28
M Takita (22682_CR2) 2020
Y Goldberg (22682_CR22) 2021; 385
CH GeurtsvanKessel (22682_CR29) 2022; 7
C Manisty (22682_CR11) 2021; 397
K Shimizu (22682_CR23) 2021; 4
T Yoshihara (22682_CR1) 2021; 18
J Tanis (22682_CR8) 2021; 100
Y Kanda (22682_CR15) 2013; 48
V Stouten (22682_CR16) 2022; 14
L Lu (22682_CR26) 2021
M Gilboa (22682_CR25) 2021
T Chano (22682_CR3) 2022; 17
P Moss (22682_CR5) 2022; 23
D Wyllie (22682_CR14) 2020
EG Levin (22682_CR21) 2021; 385
J Liu (22682_CR28) 2022; 603
APS Munro (22682_CR6) 2022
F Muecksch (22682_CR24) 2022; 607
22682_CR4
R Keeton (22682_CR27) 2022; 603
A Schaffner (22682_CR10) 2020; 9
22682_CR17
A Schallier (22682_CR9) 2021; 100
References_xml – volume: 385
  year: 2021
  ident: CR22
  article-title: Waning immunity after the BNT162b2 vaccine in Israel
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2114228
– volume: 603
  start-page: 493
  year: 2022
  end-page: 496
  ident: CR28
  article-title: Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron
  publication-title: Nature
  doi: 10.1038/s41586-022-04465-y
– year: 2022
  ident: CR7
  article-title: Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study
  publication-title: Lancet Respir. Med.
  doi: 10.1016/s2213-2600(22)00101-1
– volume: 100
  year: 2021
  ident: CR12
  article-title: Clinical evaluation of the antibody response in patients with COVID-19 using automated high-throughput immunoassays
  publication-title: Diagn. Microbiol. Infect. Dis.
  doi: 10.1016/j.diagmicrobio.2021.115370
– volume: 385
  year: 2021
  ident: CR21
  article-title: Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2114583
– volume: 607
  start-page: 128
  year: 2022
  end-page: 134
  ident: CR24
  article-title: Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost
  publication-title: Nature
  doi: 10.1038/s41586-022-04778-y
– ident: CR4
– year: 2021
  ident: CR19
  article-title: Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study
  publication-title: Lancet Reg. Health Eur.
  doi: 10.1016/j.lanepe.2021.100208
– volume: 397
  start-page: 1057
  year: 2021
  end-page: 1058
  ident: CR11
  article-title: Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
  publication-title: The Lancet
  doi: 10.1016/s0140-6736(21)00501-8
– volume: 397
  start-page: 1178
  year: 2021
  end-page: 1181
  ident: CR13
  article-title: Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine
  publication-title: The Lancet
  doi: 10.1016/s0140-6736(21)00502-x
– volume: 7
  start-page: eabo2202
  year: 2022
  ident: CR29
  article-title: Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients
  publication-title: Sci. Immunol.
  doi: 10.1126/sciimmunol.abo2202
– volume: 18
  start-page: 3786
  year: 2021
  ident: CR1
  article-title: SARS-CoV-2 seroprevalence among healthcare workers in general hospitals and clinics in Japan
  publication-title: Int. J. Environ. Res. Public Health
  doi: 10.3390/ijerph18073786
– volume: 48
  start-page: 452
  year: 2013
  end-page: 458
  ident: CR15
  article-title: Investigation of the freely available easy-to-use software 'EZR' for medical statistics
  publication-title: Bone Marrow Transplant.
  doi: 10.1038/bmt.2012.244
– volume: 185
  start-page: 1875
  year: 2022
  end-page: 1887.e1878
  ident: CR30
  article-title: Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine
  publication-title: Cell
  doi: 10.1016/j.cell.2022.04.009
– year: 2021
  ident: CR25
  article-title: Early immunogenicity and safety of the third dose of BNT162b2 mRNA Covid-19 vaccine among adults older than 60 years; real world experience
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/jiab584
– year: 2020
  ident: CR14
  article-title: SARS-CoV-2 responsive T cell numbers are associated with protection from COVID-19: A prospective cohort study in keyworkers
  publication-title: medRxiv
  doi: 10.1101/2020.11.02.20222778
– volume: 398
  start-page: 385
  year: 2021
  end-page: 387
  ident: CR20
  article-title: Spike-antibody waning after second dose of BNT162b2 or ChAdOx1
  publication-title: The Lancet
  doi: 10.1016/s0140-6736(21)01642-1
– volume: 28
  start-page: 472
  year: 2022
  end-page: 476
  ident: CR31
  article-title: Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant
  publication-title: Nat. Med.
  doi: 10.1038/s41591-022-01700-x
– volume: 17
  year: 2022
  ident: CR3
  article-title: Serology suggests adequate safety measures to protect healthcare workers from COVID-19 in Shiga Prefecture, Japan
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0270334
– volume: 23
  start-page: 186
  year: 2022
  end-page: 193
  ident: CR5
  article-title: The T cell immune response against SARS-CoV-2
  publication-title: Nat. Immunol.
  doi: 10.1038/s41590-021-01122-w
– volume: 603
  start-page: 488
  year: 2022
  end-page: 492
  ident: CR27
  article-title: T cell responses to SARS-CoV-2 spike cross-recognize Omicron
  publication-title: Nature
  doi: 10.1038/s41586-022-04460-3
– year: 2022
  ident: CR6
  article-title: Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): A multicentre, blinded, phase 2, randomised trial
  publication-title: Lancet Infect. Dis.
  doi: 10.1016/s1473-3099(22)00271-7
– volume: 14
  start-page: 802
  year: 2022
  ident: CR16
  article-title: Incidence and risk factors of COVID-19 vaccine breakthrough infections: A prospective cohort study in Belgium
  publication-title: Viruses
  doi: 10.3390/v14040802
– ident: CR17
– volume: 9
  start-page: 3989
  year: 2020
  ident: CR10
  article-title: Characterization of a pan-immunoglobulin assay quantifying antibodies directed against the receptor binding domain of the SARS-CoV-2 S1-subunit of the spike protein: A population-based study
  publication-title: J. Clin. Med.
  doi: 10.3390/jcm9123989
– volume: 4
  start-page: 1365
  year: 2021
  ident: CR23
  article-title: Identification of TCR repertoires in functionally competent cytotoxic T cells cross-reactive to SARS-CoV-2
  publication-title: Commun. Biol.
  doi: 10.1038/s42003-021-02885-6
– year: 2021
  ident: CR26
  article-title: Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients
  publication-title: Clin. Infect. Dis.
  doi: 10.1093/cid/ciab1041
– volume: 371
  year: 2020
  ident: CR18
  article-title: Covid-19: Risks to healthcare workers and their families
  publication-title: BMJ
  doi: 10.1136/bmj.m3944
– year: 2020
  ident: CR2
  article-title: Preliminary results of seroprevalence of SARS-CoV-2 at community clinics in Tokyo
  publication-title: medRxiv
  doi: 10.1101/2020.04.29.20085449
– volume: 100
  year: 2021
  ident: CR9
  article-title: Assay dependence of long-term kinetics of SARS-CoV-2 antibodies
  publication-title: Diagn. Microbiol. Infect. Dis.
  doi: 10.1016/j.diagmicrobio.2021.115403
– volume: 100
  year: 2021
  ident: CR8
  article-title: Evaluation of four laboratory-based SARS-CoV-2 IgG antibody immunoassays
  publication-title: Diagn. Microbiol. Infect. Dis.
  doi: 10.1016/j.diagmicrobio.2021.115313
– volume: 18
  start-page: 3786
  year: 2021
  ident: 22682_CR1
  publication-title: Int. J. Environ. Res. Public Health
  doi: 10.3390/ijerph18073786
– year: 2020
  ident: 22682_CR14
  publication-title: medRxiv
  doi: 10.1101/2020.11.02.20222778
– year: 2022
  ident: 22682_CR6
  publication-title: Lancet Infect. Dis.
  doi: 10.1016/s1473-3099(22)00271-7
– volume: 371
  year: 2020
  ident: 22682_CR18
  publication-title: BMJ
  doi: 10.1136/bmj.m3944
– volume: 17
  year: 2022
  ident: 22682_CR3
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0270334
– year: 2021
  ident: 22682_CR19
  publication-title: Lancet Reg. Health Eur.
  doi: 10.1016/j.lanepe.2021.100208
– volume: 23
  start-page: 186
  year: 2022
  ident: 22682_CR5
  publication-title: Nat. Immunol.
  doi: 10.1038/s41590-021-01122-w
– volume: 385
  year: 2021
  ident: 22682_CR21
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2114583
– volume: 28
  start-page: 472
  year: 2022
  ident: 22682_CR31
  publication-title: Nat. Med.
  doi: 10.1038/s41591-022-01700-x
– volume: 4
  start-page: 1365
  year: 2021
  ident: 22682_CR23
  publication-title: Commun. Biol.
  doi: 10.1038/s42003-021-02885-6
– volume: 9
  start-page: 3989
  year: 2020
  ident: 22682_CR10
  publication-title: J. Clin. Med.
  doi: 10.3390/jcm9123989
– volume: 603
  start-page: 488
  year: 2022
  ident: 22682_CR27
  publication-title: Nature
  doi: 10.1038/s41586-022-04460-3
– volume: 100
  year: 2021
  ident: 22682_CR9
  publication-title: Diagn. Microbiol. Infect. Dis.
  doi: 10.1016/j.diagmicrobio.2021.115403
– volume: 397
  start-page: 1178
  year: 2021
  ident: 22682_CR13
  publication-title: The Lancet
  doi: 10.1016/s0140-6736(21)00502-x
– volume: 14
  start-page: 802
  year: 2022
  ident: 22682_CR16
  publication-title: Viruses
  doi: 10.3390/v14040802
– year: 2022
  ident: 22682_CR7
  publication-title: Lancet Respir. Med.
  doi: 10.1016/s2213-2600(22)00101-1
– volume: 603
  start-page: 493
  year: 2022
  ident: 22682_CR28
  publication-title: Nature
  doi: 10.1038/s41586-022-04465-y
– volume: 100
  year: 2021
  ident: 22682_CR12
  publication-title: Diagn. Microbiol. Infect. Dis.
  doi: 10.1016/j.diagmicrobio.2021.115370
– year: 2021
  ident: 22682_CR26
  publication-title: Clin. Infect. Dis.
  doi: 10.1093/cid/ciab1041
– year: 2020
  ident: 22682_CR2
  publication-title: medRxiv
  doi: 10.1101/2020.04.29.20085449
– volume: 385
  year: 2021
  ident: 22682_CR22
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2114228
– volume: 100
  year: 2021
  ident: 22682_CR8
  publication-title: Diagn. Microbiol. Infect. Dis.
  doi: 10.1016/j.diagmicrobio.2021.115313
– ident: 22682_CR4
– volume: 48
  start-page: 452
  year: 2013
  ident: 22682_CR15
  publication-title: Bone Marrow Transplant.
  doi: 10.1038/bmt.2012.244
– volume: 607
  start-page: 128
  year: 2022
  ident: 22682_CR24
  publication-title: Nature
  doi: 10.1038/s41586-022-04778-y
– volume: 7
  start-page: eabo2202
  year: 2022
  ident: 22682_CR29
  publication-title: Sci. Immunol.
  doi: 10.1126/sciimmunol.abo2202
– volume: 397
  start-page: 1057
  year: 2021
  ident: 22682_CR11
  publication-title: The Lancet
  doi: 10.1016/s0140-6736(21)00501-8
– volume: 185
  start-page: 1875
  year: 2022
  ident: 22682_CR30
  publication-title: Cell
  doi: 10.1016/j.cell.2022.04.009
– volume: 398
  start-page: 385
  year: 2021
  ident: 22682_CR20
  publication-title: The Lancet
  doi: 10.1016/s0140-6736(21)01642-1
– ident: 22682_CR17
– year: 2021
  ident: 22682_CR25
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/jiab584
SSID ssj0000529419
Score 2.3972106
Snippet This study, which included serological and cellular immunity tests, evaluated whether coronavirus disease 2019 (COVID-19) vaccination adequately protected...
Abstract This study, which included serological and cellular immunity tests, evaluated whether coronavirus disease 2019 (COVID-19) vaccination adequately...
SourceID doaj
unpaywall
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 17621
SubjectTerms 631/250/255/2514
692/699/255/2514
Cell-mediated immunity
Coronaviruses
COVID-19
COVID-19 - epidemiology
COVID-19 - prevention & control
COVID-19 Vaccines
Health care
Health Personnel
Humanities and Social Sciences
Humans
Immune response (humoral)
Immunoglobulin G
Immunoglobulin M
Japan - epidemiology
Medical personnel
multidisciplinary
SARS-CoV-2
Science
Science (multidisciplinary)
Serology
Severe acute respiratory syndrome coronavirus 2
Vaccination
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB6hShVwQC3PQEFG4sZGjR-b2EcorUolHhK06s2yHbu70ipb0V1Q_z1jOxt2BSocuOTgOJEzj8w3fnwD8CqSSOWptxovggZfWs9CaRvHGvQnE3g8KPzhY318Kk7Ox-drpb7inrBMD5wFt4-QgjIvnQwcg2drJMeUhDPbGoNvbxM0qqRaS6YyqzdTgqr-lEzF5f4VRqp4mgxzL0QcCCv5RiRKhP1_Qpm_b5YcVkzvwu1ld2muf5jZbC0oHe3AvR5Nkjf5K3bhlu_uw3auL3n9AM4yN3H_QyPzQA4-nb1_V1JFvhvnpnkmkEw7Mhm2gZG4UwsxYWz9MpleGPI5liJJKw0jcoKxtXsIp0eHXw-Oy76QQukQgC3KgLjABOfrxgQE060IRnrb0nYsjaid9YFTJ6kY8yCsDDRUCoVbNR7RYiuF5Y9gq5t3_gkQ0xjjbEVd23KhpFXCV5aKwOoEF0MBdCVU7XqW8VjsYqbTajeXOitCoyJ0UoTmBbwenrnMHBs39n4bdTX0jPzYqQGtRvdWo_9mNQXsrTSte6e90gyxHOZbnKsCXg630d3iGorp_HyZ-0RQp7DP42wYw0gQCzSxRE4BzYbJbAx18043nSRKbzWWNWaqBYxWxvVrWDeJYjQY4D9I7un_kNwzuMOiE2H4ZnQPthbflv454rKFfZFc8CfWnzAR
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LbxMxEB6VVAh6QLwKSwsyEjeyarx2dr0HVNGXSiVCBbTqzfKziRTthjYp6r9nvK82AkVc9mB7Jdsz4_nssb8B-BBIpOqjtxQ_nHoXa5f4WGcmydCelGfhofDXUXp8xk8uhhdrMGrfwoRrle2aWC3UtjThjHwnQUeLYJixfHf2Kw5Zo0J0tU2hoZrUCvZTRTH2ANaTwIzVg_W9w9Hp9-7UJcS1OM2b1zMDJnau0YOFV2a4J0MkgnCTLXmoisj_X-jz70uUXSR1Ax4tipm6_a2m03vO6ugpPGlQJvlcq8UzWHPFc3hY5528fQHnNWdxs9CR0pP9b-dfDmKakxsc46Q-ISSTgoy762Ek3OBCrBhKf4wnl4qchhQlVQSiT07Q5xYv4ezo8Of-cdwkWIgNArN57BEvKG9cmimPINtyr4TTltqhUDw12nlGjaB8yDzXwlM_yBXCrcwhirSCa7YJvaIs3GsgKlPK6AE11jKeC51zN9CU-yStYKSPgLaTKk3DPh6SYExlFQVnQtaCkCgIWQlCsgg-dv_Mau6Nla33gqy6loE3uyoory5lY4YSASpNnDDCM4RiVgmGG1yWaKtwYNSqCLZbScvGmK_lnepF8L6rRjMMsRVVuHJRtwlgL8c2r2rF6HqCGCELqXMiyJZUZqmryzXFZFxRfedDkeIONoJ-q1x33Vo1Ff1OAf9j5t6sHvQWPE6CeaDDTug29OZXC_cWkdhcv2vM6w_8YS6A
  priority: 102
  providerName: ProQuest
– databaseName: HAS SpringerNature Open Access 2022
  dbid: AAJSJ
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlZ3dT9swEMBPrGja9oD2BcuAyZP2tkarYzdxHgsMsUqDSQzEm-VPWqlK0Wg38d_vHKeBiAmxlz4kduX67no_--w7gE8hiVTcesvxg1PvUu0yn-rCZAXak_IsXBT-fpwfnfHxxfBiDfqruzCd-H2duvsaXUy4BoaLJkQF5EH2BNYFKqbowfpoND4dt3sqIWrFadncjcHuX-537vifOk3_v9jy_hHJNk76Ap4tqyt180fNZndc0eFL2GgYkoyi0F_Bmqtew9NYVfLmDZzHjMTN3xiZe7J_cv7tIKUl-a2Mmcb9PzKtyKQ9_EXC-SwkwfD0dDK9VORHKEBSxxf6ZIwetXoLZ4dff-4fpU35hNQgdi1SjzSgvHF5oTwitOVeCacttUOheG6084waQfmQea6Fp35QKoSpwiEjWsE124ReNa_cOyCqUMroATXWMl4KXXI30JT7LK8h0SdAV5MqTZNbPJS4mMk6xs2EjIKQKAhZC0KyBD63fa5iZo0HW-8FWbUtQ1bs-gEqi2yMTCJ-0swJIzxD0LJKMFy-skxbhT-MWpXAzkrSsjHVa5khweEqi7EygY_tazSyEDlRlZsvY5uAciW22YqK0Y4ECaAIhXESKDoq0xlq9001ndSJvMuhyHF9mkB_pVy3w3poKvqtAj5i5t7_37dvw_MsmAu654zuQG_xa-l2kbsW-kNjbn8BUsEirw
  priority: 102
  providerName: Springer Nature
– databaseName: Unpaywall
  dbid: UNPAY
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlZ3db9MwEMBPoxMCHvhmCwwUJN5otjp2E-dxDKYxiTEJOsaT5c-1okqnrQWNv56znQQK08Re8pBcJPty9v0cn-8AXvkkUvHXW4EXRpzNlM1dpkqdlziepKP-oPCHg2JvxPaPh8crULRnYULQfkhpGabpNjps6xwdjT8MhksnBAakQlwCGncDVoshMngPVkcHh9tffSU5ZJQMMSFvTsgMKL_k5SUvFJL1X0aY_wZKdruld-DWoj6VFz_kdPqHQ9q9B1_arsQ4lG-bi7na1D__yvJ4_b7eh7sNo6bbUfIBrNj6IdyMVSsvHsFRzHjcTJPpzKU7H4_ev81IlX6XWk_i_8V0UqfjLrgs9fFfSJr-7qfx5ESmh77ASdi_6Kf76LHrxzDaffd5Zy9ryjNkGrFunjmkDem0LUrpENENc5JbZYgZcskKrayjRHPChtQxxR1xg0oirJUWGdRwpugT6NWz2q5DKksptRoQbQxlFVcVswNFmMuLAKEuAdJ-LqGb3OW-hMZUhD10ykXUmUCdiaAzQRN43b1zGjN3XCn9xltBJ-mzbocbs7MT0XwZgXhLcss1dxRBzkhOcXlMc2UkdowYmcBGa0OimQrORY6EiKs4SqsEXnaPcRD7nRlZ29kiynhUrFBmLZpc1xIkjNIX3kmgXDLGpaYuP6kn45AovBryAte_CfRbs_3drKtU0e9M-z809_R64s_gdu4tG91_TjagNz9b2OfIdXP1ohnEvwBzSEU8
  priority: 102
  providerName: Unpaywall
Title Effectiveness of COVID-19 vaccination in healthcare workers in Shiga Prefecture, Japan
URI https://link.springer.com/article/10.1038/s41598-022-22682-3
https://www.ncbi.nlm.nih.gov/pubmed/36271136
https://www.proquest.com/docview/2727118339
https://www.proquest.com/docview/2727639999
https://pubmed.ncbi.nlm.nih.gov/PMC9586956
https://www.nature.com/articles/s41598-022-22682-3.pdf
https://doaj.org/article/05412e8c8f3643da8384032bdaa611da
UnpaywallVersion publishedVersion
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVFSB
  databaseName: Free Full-Text Journals in Chemistry
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: HH5
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://abc-chemistry.org/
  providerName: ABC ChemistRy
– providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: KQ8
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: DOA
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVEBS
  databaseName: EBSCOhost Academic Search Ultimate
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: ABDBF
  dateStart: 20121221
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: DIK
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: GX1
  dateStart: 0
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: M~E
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: RPM
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVAQT
  databaseName: Springer Nature - nature.com Journals - Fully Open Access
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: NAO
  dateStart: 20111201
  isFulltext: true
  titleUrlDefault: https://www.nature.com/siteindex/index.html
  providerName: Nature Publishing
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: 7X7
  dateStart: 20210101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: BENPR
  dateStart: 20210101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 20250131
  omitProxy: true
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: M48
  dateStart: 20110801
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
– providerCode: PRVAVX
  databaseName: HAS SpringerNature Open Access 2022
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: AAJSJ
  dateStart: 20111201
  isFulltext: true
  titleUrlDefault: https://www.springernature.com
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: Springer Nature OA Free Journals
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: C6C
  dateStart: 20111201
  isFulltext: true
  titleUrlDefault: http://www.springeropen.com/
  providerName: Springer Nature
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3db9MwEMBP-xACHhDfBEYVJN5ooI7dxHlAqCubRqWVitGpe7Jsx14rVenoWqD_Pec4DVRUE-IllWxHcu273O_8cQfw2gWR8ktvCT4YsSZSJraRSnWcoj5JS91F4dN-cjJkvVF7tAPrdEfVAF5vde1cPqnhfPr257fVB1T49_7KOH93jUbIXRRDtwphAomR7sI-WqrMpXI4rXDfx_qOM0ay6u7M9lc37FMZxn8be_59hLLeR70Lt5fFlVz9kNPpH6bq-D7cqxgz7HiheAA7pngIt3zWydUjOPcRi6vPXDizYffz-aePEcnC71LriV8fDCdFOK4Ph4Xu_BaSois9G08uZThwCUrK_Ydm2EOLWzyG4fHR1-5JVKVXiDRi2SKySAvSapOk0iJi58xKblRO8jaXLNHKWEo0J6xNLVPcEtvKJMJWapAhc84UfQJ7xawwzyCUqZRatYjOc8oyrjJmWoowGyclRNoAyHpQha5ij7sUGFNR7oFTLvxECJwIUU6EoAG8qd-58pE3bmx96OaqbumiZpcFs_mlqJRQIJ6S2HDNLUUQyyWn6N7SWOUS_xjJZQAH65kWa0kUMRIeemGUZgG8qqtRCd3OiizMbOnbONTLsM1TLxh1T5AQUpc4J4B0Q2Q2urpZU0zGZaDvrM0T9F8DaK6F63e3bhqKZi2A_zByz_-7Xy_gTuw0By15TA5gbzFfmpeIaAvVgN10lDZgv9PpnfXw9_CoP_iCpd2k2yiXPRqlZmLNsD_oXPwCVKE-ZA
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NTWjwgPgmMCBI8ESj1bGbOA8TYl9q91Em2Ka9GTu210pVUtaWqf8cfxvnfI0KVPGylzwkTuTch-93Pt8dwHtXRKrceovwwog1gTKhDVSchjHqk7TUJQof96PuGTu46FyswK86F8Ydq6zXxGKh1nnq9sg3QzS0CIYpTT6NfwSua5SLrtYtNGTVWkFvFSXGqsSOQzO_RhdustXbRX5_CMP9vdOdblB1GQhSRCfTwKLRlDY1USwtIk3NrORGaaI7XLIoVcZSknLCOtQyxS2x7UQi5ogNQinNmaL43TuwxihL0Plb297rn3xtdnlcHI2RpMrWaVO-OUGL6bLa0AdE5IPwli5YxKJxwL_Q7t-HNpvI7X1Yn2VjOb-Wo9EfxnH_ITyoUK3_uRTDR7Bissdwt-xzOX8C52WN5Gph9XPr73w57-0GJPF_Ik2H5Y6kP8z8QXMczXcnxhCburvfBsNL6Z-4lihFxKPlH6CNz57C2a2Q-hmsZnlmXoAvYylT1Sap1kh4rhJm2oowG0YFbLUekJqoIq2qnbumGyNRRN0pFyUjBDJCFIwQ1IOPzTvjstbH0tHbjlfNSFenu7iRX12KSu0FAmISGp5ySxH6ackpOtQ0VFrijxEtPdioOS2qxWMibkTdg3fNY1R7F8uRmcln5RgHLhMc87wUjGYmiEli16rHg3hBZBamuvgkGw6K0uJJh0foMXvQqoXrZlrLSNFqBPA_KPdy-U-_hfXu6fGROOr1D1_BvdCpCoKFkGzA6vRqZl4jCpyqN5Wq-fD9trX7N7l-bMI
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LbxMxEB6VIl4HxJuFAkaCE1klXju73gNC0BA1LZRK0Co3Y3vtJlK0CU1Clb_Gr2O8rxKBIi697MHrXdmeGc83nvEMwCufRKo8eovxwamzobaRC3ViogTlSTnmLwp_Poz3jvn-sDvcgl_1XRgfVlnvicVGnU2NPyNvR6hoEQwzlrZdFRZx1Ou_m_0IfQUp72mty2mULHJgV-dovs3fDnpI69dR1P_4bXcvrCoMhAaRySJ0qDCVMzZOlEOUmXGnhNUZzbpC8dho6xg1gvIuc1wLR10nVYg3EoswKhNcM_zvFbia4Kh8OGEyTJrzHe9B4zSt7ul0mGjPUVf6-2xo_SHmQWDL1nRhUTLgXzj373DNxmd7C24s85lanavJ5A-12L8Dtys8S96XDHgXtmx-D66VFS5X9-GkzI5cbalk6sjul5NBL6Qp-amMGZdnkWSck1ETiEZ8rBiiUt_6dTQ-VeTIF0MpfB0tso_aPX8Ax5ey0A9hO5_m9jEQlShldIeaLGM8FTrltqMpd1FcAFYXAK0XVZoqz7kvtzGRhb-dCVkSQiIhZEEIyQJ403wzK7N8bOz9wdOq6ekzdBcN07NTWQm8RChMIyuMcAxBX6YEQ1OaRTpTODGaqQB2akrLatuYywsmD-Bl8xoF3ntxVG6ny7KPh5Up9nlUMkYzEkQjiS_SE0CyxjJrQ11_k49HRVLxtCtitJUDaNXMdTGsTUvRahjwP1buyeZJv4DrKNPy0-Dw4CncjLykIEqI6A5sL86W9hnCv4V-XsgZge-XLdi_AbJ9alw
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlZ3db9MwEMBPoxMCHvhmCwwUJN5otjp2E-dxDKYxiTEJOsaT5c-1okqnrQWNv56znQQK08Re8pBcJPty9v0cn-8AXvkkUvHXW4EXRpzNlM1dpkqdlziepKP-oPCHg2JvxPaPh8crULRnYULQfkhpGabpNjps6xwdjT8MhksnBAakQlwCGncDVoshMngPVkcHh9tffSU5ZJQMMSFvTsgMKL_k5SUvFJL1X0aY_wZKdruld-DWoj6VFz_kdPqHQ9q9B1_arsQ4lG-bi7na1D__yvJ4_b7eh7sNo6bbUfIBrNj6IdyMVSsvHsFRzHjcTJPpzKU7H4_ev81IlX6XWk_i_8V0UqfjLrgs9fFfSJr-7qfx5ESmh77ASdi_6Kf76LHrxzDaffd5Zy9ryjNkGrFunjmkDem0LUrpENENc5JbZYgZcskKrayjRHPChtQxxR1xg0oirJUWGdRwpugT6NWz2q5DKksptRoQbQxlFVcVswNFmMuLAKEuAdJ-LqGb3OW-hMZUhD10ykXUmUCdiaAzQRN43b1zGjN3XCn9xltBJ-mzbocbs7MT0XwZgXhLcss1dxRBzkhOcXlMc2UkdowYmcBGa0OimQrORY6EiKs4SqsEXnaPcRD7nRlZ29kiynhUrFBmLZpc1xIkjNIX3kmgXDLGpaYuP6kn45AovBryAte_CfRbs_3drKtU0e9M-z809_R64s_gdu4tG91_TjagNz9b2OfIdXP1ohnEvwBzSEU8
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effectiveness+of+COVID-19+vaccination+in+healthcare+workers+in+Shiga+Prefecture%2C+Japan&rft.jtitle=Scientific+reports&rft.au=Chano%2C+Tokuhiro&rft.au=Yamashita%2C+Tomoko&rft.au=Fujimura%2C+Hirokazu&rft.au=Kita%2C+Hiroko&rft.date=2022-10-21&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2045-2322&rft.volume=12&rft_id=info:doi/10.1038%2Fs41598-022-22682-3&rft.externalDocID=PMC9586956
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon